MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

Abstract

Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas. The O-6-methylguanine-DNA methyltransferase (MGMT) is responsible for the direct repair of the main TMZ-induced toxic DNA adduct, the O6-Methylguanine lesion. MGMT promoter hypermethylation is currently the only known biomarker for TMZ response in glioblastoma patients. Here we show that a subset of recurrent gliomas carries MGMT genomic rearrangements that lead to MGMT overexpression, independently from changes in its promoter methylation. By leveraging the CRISPR/Cas9 technology we generated some of these MGMT rearrangements in glioma cells and demonstrated that the MGMT genomic rearrangements contribute to TMZ resistance both in vitro and in vivo. Lastly, we showed that such fusions can be detected in tumor-derived exosomes and could potentially represent an early detection marker of tumor recurrence in a subset of patients treated with TMZ.

References 37

1. 1.

   Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair. 2007;6:1079-1099.

   Not in our library10.1016/j.dnarep.2007.03.008

2. 2.

   Zhang J, Stevens MFG, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 2012;5:102-114.

   Not in our library10.2174/1874467211205010102

3. 3.

   Esteller M, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000;343:1350-1354.

   Not in our library10.1056/nejm200011093431901

4. 4.

   Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005;352:997-1003.

   Not in our library10.1056/nejmoa043331

5. 5.
   A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma · 2018

   No notice
6. 6.

   Kreth S, et al. O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS ONE. 2011;6:e17156.

   Not in our library10.1371/journal.pone.0017156

7. 7.

   Wang J, et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 2016;48:768-776.

   Not in our library10.1038/ng.3590

8. 8.

   Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. World Health Organization Histological Classification of Tumours of the Central Nervous System. (International Agency for Research on Cancer, France, 2016).

   Not in our library

9. 9.

   van den Bent MJ, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390:1645-1653.

   Not in our library10.1016/s0140-6736(17)31442-3

10. 10.

    Maddalo D, et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature. 2014;516:423-427.

    Not in our library10.1038/nature13902

11. 11.

    Oldrini B, et al. Somatic genome editing with the RCAS-TVA- CRISPR-Cas9 system for precision tumor modeling. Nat. Commun. 2018.

    Not in our library10.1101/162669

12. 12.
    deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data · 2011

    No notice
13. 13.
    Driver Fusions and Their Implications in the Development and Treatment of Human Cancers · 2018

    No notice
14. 14.

    Annala MJ, Parker BC, Zhang W, Nykter M. Fusion genes and their discovery using high throughput sequencing. Cancer Lett. 2013;340:192-200.

    Not in our library10.1016/j.canlet.2013.01.011

15. 15.

    Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl Acad. Sci. USA. 1990;87:5368-5372.

    Not in our library10.1073/pnas.87.14.5368

16. 16.
    DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients · 2016

    No notice
17. 17.
    Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma · 2015

    No notice
18. 18.

    Zeng A-L, et al. Tumour exosomes from cells harbouring PTPRZ1–MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma. Oncogene. 2017;36:5369-5381.

    Not in our library10.1038/onc.2017.134

19. 19.

    Felsberg J, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int. J. Cancer. 2011;129:659-670.

    Not in our library10.1002/ijc.26083

20. 20.

    Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462-477.

    Not in our library10.1016/j.cell.2013.09.034

21. 21.

    Dupain C, et al. Discovery of new fusion transcripts in a cohort of pediatric solid cancers at relapse and relevance for personalized medicine. Mol. Ther. 2019;27:200-218.

    Not in our library10.1016/j.ymthe.2018.10.022

22. 22.

    Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro. Oncol. 2013;15:4-27.

    Not in our library10.1007/s10269-013-2247-5

23. 23.

    Weller M, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin. Cancer Res. 2015;21:2057-2064.

    Not in our library10.1158/1078-0432.ccr-14-2737

24. 24.

    Hegi ME, et al. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials. Clin. Cancer Res. 2019;25:1809-1816.

    Not in our library10.1158/1078-0432.ccr-18-3181

25. 25.

    Hu H, et al. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 2018;175:1665-1678.e18.

    Not in our library10.1016/j.cell.2018.09.038

26. 26.

    Bao Z-S, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014;24:1765-1773.

    Not in our library10.1101/gr.165126.113

27. 27.

    Ceccarelli M, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164:550-563.

    Not in our library10.1016/j.cell.2015.12.028

28. 28.
    Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas · 2017

    No notice
29. 29.

    Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.

    Not in our library10.1093/bioinformatics/bts635

30. 30.

    Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923-930.

    Not in our library10.1093/bioinformatics/btt656

31. 31.

    Li H, et al. The sequence alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078-2079.

    Not in our library10.1093/bioinformatics/btp352

32. 32.
    Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods · 2019

    No notice
33. 33.

    Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at http://arxiv.org/abs/1303.3997 (2013).

    Not in our library

34. 34.

    Chen X, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32:1220-1222.

    Not in our library10.1093/bioinformatics/btv710

35. 35.

    Mu, Q. & Wang, J. CNAPE: a machine learning method for copy number alteration prediction from gene expression. IEEE/ACM Trans. Comput. Biol. Bioinform. 10.1109/TCBB.2019.2944827 (2019).

    Not in our library10.1109/tcbb.2019.2944827

36. 36.

    Jiang, B., Song, D., Mu, Q. & Wang, J. CELLO: a longitudinal data analysis toolbox untangling cancer evolution. Quant. Biol. 10.1007/s40484-020-0218-1 (2020).

    Not in our library

37. 37.

    Ponomarev V, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur. J. Nucl. Med. Mol. Imaging. 2004;31:740-751.

    Not in our library10.1007/s00259-003-1441-5

Cited by papers we hold 5

• DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities · 2022
  No notice
• Glioma targeted therapy: insight into future of molecular approaches · 2022
  No notice
• Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma · 2021
  No notice
• YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma · 2021
  No notice
• Glioma: molecular signature and crossroads with tumor microenvironment · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.